TScan director granted options on 67,000 shares

TScan Therapeutics director Keith Woods received a new stock option grant covering 67,000 shares of Voting Common Stock.

Rhea-AI Filing Summary

TScan Therapeutics director Keith Woods received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. All 67,000 underlying shares vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options for 67,000 shares directly.

Insider Trade Summary

Grant/Award: 67,000 shares

Grant/Award 1 txn

Insider Woods Keith

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	67,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 67,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Key Figures

Option grant size: 67,000 shares Exercise price: $0.9946 per share Expiration date: May 20, 2036 +2 more

5 metrics

Option grant size 67,000 shares Stock Option (Right to Buy) underlying Voting Common Stock

Exercise price $0.9946 per share Exercise price for granted stock options

Expiration date May 20, 2036 Option expiration for 67,000-share grant

Post-grant option holdings 67,000 options Total derivative shares following this grant

Vesting date trigger Earlier of May 20, 2027 or next annual meeting Full vesting condition subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, Voting Common Stock, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 0.9946"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Voting Common Stock financial

"underlying_security_title: Voting Common Stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Keith Woods report in this TScan Therapeutics (TCRX) Form 4?

Keith Woods reported receiving a stock option grant for 67,000 shares of Voting Common Stock. The option was awarded as compensation, not purchased on the open market, and represents a new derivative position in TScan Therapeutics equity.

What is the exercise price of Keith Woods’ new TCRX stock options?

The new stock options have an exercise price of $0.9946 per share. This is the price at which Woods can buy TScan Therapeutics Voting Common Stock if and when the options vest and he chooses to exercise them.

When do Keith Woods’ TScan Therapeutics options vest and become exercisable?

All 67,000 options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders. Vesting is conditioned on Woods’ continued service with TScan Therapeutics through that time.

How many TScan Therapeutics shares are covered by Keith Woods’ new option?

The option grant covers 67,000 underlying shares of TScan Therapeutics Voting Common Stock. These shares can be acquired in the future by exercising the option after it vests, at the stated exercise price of $0.9946 per share.

Is Keith Woods’ Form 4 transaction a market purchase or sale of TCRX stock?

The Form 4 shows a grant of stock options, categorized as a grant or award acquisition. It is not an open-market purchase or sale but a compensation-related award giving Woods the right to buy shares in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woods Keith

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9946	05/20/2026		A		67,000		(1)	05/20/2036	Voting Common Stock	67,000	$0.00	67,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Zoran Zdraveski, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)